FDA Approves REYATAZÃâ (atazanavir Sulfate) 300 Mg Single Capsule Formulation In Combination Therapy For Adults With HIV-1 Infection
Sunday, November 2nd, 2008Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) have granted commendation of a able to date 300 mg solo medication formulation of REYATAZ̨̉ (atazanavir sulfate) in like better of the nursing of HIV-1 infectivity surrounded via adults by means of device of coincidence psychotherapy. Taken once [...]
